1. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. (December 2019) Authors: Qin, Shukui; Chan, Stephen Lam; Sukeepaisarnjaroen, Wattana; Han, Guohong; Choo, Su Pin; Sriuranpong, Virote; Pan, Hongming; Yau, Thomas; Guo, Yabing; Chen, Minshan; Ren, Zhenggang; Xu, Jianming; Yen, Chia-Jui; Lin, Zhong-Zhe; Manenti, Luigi; Gu, Yi; Sun, Yongjian; Tiedt, Ralph; Hao, Lu; Song, We... Journal: Therapeutic advances in medical oncology Issue: Volume 11(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy . (21st December 2021) Authors: Liu, Shi; Deng, Rui; Zhou, Bin; Liang, Xieer; Liu, Zhihong; Peng, Jie; Chen, Jinjun; Zhou, Yuanping; Guo, Yabing; Chen, Yongpeng; Li, Wanying; Shen, Sheng; Lu, Xingyu; Zhao, Siru; Liao, Xingmei; Liang, Hongyan; Lan, Yu; Hou, Jinlin; Fan, Rong; Sun, Jian Journal: Journal of infectious diseases Issue: Volume 226:Number 5(2022) Page Start: 881 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cancer immunotherapy with multiple tumor antigen activated autologous T cells in patients with HBV related hepatocellular carcinoma. (6th November 2014) Authors: Han, Yanyan; Tao, Ran; Huang, Jin; Guo, Yabing; Wu, Dongyun; Liao, Yujing; Li, Jin; Zhou, Xiangjun; Hou, Jinlin Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma. (May 2021) Authors: Liu, Dan; Ma, Chunguang; Lu, Ping; Gong, Jifang; Ye, Dingwei; Wang, Siyang; Peng, Peijian; Bai, Yuxian; Song, Yuqin; Chen, Jianhua; Jiang, Ou; Zhang, Guojun; Ba, Yi; Chen, Li; Pan, Jianji; Li, Qi; Zhang, Liling; Gu, Shanzhi; Yin, Xianli; Cao, Bangwei Journal: European journal of cancer Issue: Volume 148(2021) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Knockdown of long non‐coding RNA MALAT1 inhibits growth and motility of human hepatoma cells via modulation of miR‐195. Issue 2 (18th September 2017) Authors: Liu, Dingli; Zhu, Yun; Pang, Jinke; Weng, Xie; Feng, Xiaorong; Guo, Yabing Journal: Journal of cellular biochemistry Issue: Volume 119:Issue 2(2018) Page Start: 1368 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study. (December 2022) Authors: Shao, Guoliang; Bai, Yuxian; Yuan, Xianglin; Chen, Xiaomin; Gu, Shanzhi; Gu, Kangsheng; Hu, Chunhong; Liang, Houjie; Guo, Yabing; Wang, Jufeng; Yen, Chia-Jui; Lee, Victor Ho-Fun; Wang, Chunxiao; Widau, Ryan C.; Zhang, Wanli; Liu, Junjun; Zhang, Qiang; Qin, Shukui Journal: EClinicalMedicine Issue: Volume 54(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Retracted: Knockdown of long non‐coding RNA MALAT1 inhibits growth and motility of human hepatoma cells via modulation of miR‐195. Issue 2 (18th September 2017) Authors: Liu, Dingli; Zhu, Yun; Pang, Jinke; Weng, Xie; Feng, Xiaorong; Guo, Yabing Journal: Journal of cellular biochemistry Issue: Volume 119:Issue 2(2018) Page Start: 1368 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Issue 7 (July 2021) Authors: Ren, Zhenggang; Xu, Jianming; Bai, Yuxian; Xu, Aibing; Cang, Shundong; Du, Chengyou; Li, Qiu; Lu, Yinying; Chen, Yajin; Guo, Yabing; Chen, Zhendong; Liu, Baorui; Jia, Weidong; Wu, Jian; Wang, Junye; Shao, Guoliang; Zhang, Bixiang; Shan, Yunfeng; Meng, Zhiqiang; Wu, Jianbing Journal: Lancet oncology Issue: Volume 22:Issue 7(2021) Page Start: 977 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Unexpected high retention of 15N‐labeled nitrogen in a tropical legume forest under long‐term nitrogen enrichment. (28th November 2021) Authors: Mao, Jinhua; Mao, Qinggong; Gundersen, Per; Gurmesa, Geshere A.; Zhang, Wei; Huang, Juan; Wang, Senhao; Li, Andi; Wang, Yufang; Guo, Yabing; Liu, Rongzhen; Mo, Jiangming; Zheng, Mianhai Journal: Global change biology Issue: Volume 28:Number 4(2022) Page Start: 1529 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Withdrawn: Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real‐world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Issue 10 (17th September 2020) Authors: Yuan, Guosheng; Hu, Xiaoyun; Li, Qi; Dai, Wencong; Cheng, Xiao; Ying, Pengfei; Yu, Wenxuan; Guo, Yabing; Chen, Mian; Chen, Jinzhang Journal: British journal of clinical pharmacology Issue: Volume 86:Issue 10(2020) Page Start: 2102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗